The deal is the result of restructuring a collaboration, which began in 2020 to develop mRNA-based vaccines for infectious diseases, into a new licensing agreement, GSK added. As a result of the collaboration, the two companies have vaccine candidates for seasonal influenza and COVID-19 in phase II clinical development and avian influenza in phase I clinical development.
Breaking
Sergey Lavrov has criticized the IMF and World Bank for allocating more aid to Ukraine than to the entire African continent...
“Superman” actor Sean Gunn doubled down on his director brother's political messaging by taking aim at Trump supporters...
Kenya’s human rights commission has accused police of operating alongside “armed criminal gangs” during the latest demonstrations...
loading...